| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Off label use--label off use?
|
Ann Oncol
|
2003
|
1.75
|
|
2
|
Use of L-asparaginase in childhood ALL.
|
Crit Rev Oncol Hematol
|
1998
|
1.69
|
|
3
|
Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93. AML-BFM Study Group.
|
Leukemia
|
2001
|
1.67
|
|
4
|
Critical limb ischaemia: initial treatment and predictors of amputation-free survival.
|
Eur J Vasc Endovasc Surg
|
2011
|
1.49
|
|
5
|
Unilateral nephrectomy and cisplatin as risk factors of ifosfamide-induced nephrotoxicity: analysis of 120 patients.
|
J Clin Oncol
|
1994
|
1.24
|
|
6
|
Dose reduction of asparaginase under pharmacokinetic and pharmacodynamic control during induction therapy in children with acute lymphoblastic leukaemia.
|
Br J Haematol
|
1997
|
1.13
|
|
7
|
Megalin genetic polymorphisms and individual sensitivity to the ototoxic effect of cisplatin.
|
Pharmacogenomics J
|
2007
|
1.13
|
|
8
|
Pharmacokinetic, pharmacodynamic and intracellular effects of PEG-asparaginase in newly diagnosed childhood acute lymphoblastic leukemia: results from a single agent window study.
|
Leukemia
|
2008
|
1.12
|
|
9
|
Pharmacokinetics of native Escherichia coli asparaginase (Asparaginase medac) and hypersensitivity reactions in ALL-BFM 95 reinduction treatment.
|
Br J Haematol
|
2001
|
1.02
|
|
10
|
Pharmacokinetic dose adjustment of Erwinia asparaginase in protocol II of the paediatric ALL/NHL-BFM treatment protocols.
|
Br J Haematol
|
1999
|
1.01
|
|
11
|
Pegylated asparaginase (Oncaspar) in children with ALL: drug monitoring in reinduction according to the ALL/NHL-BFM 95 protocols.
|
Br J Haematol
|
2000
|
1.00
|
|
12
|
Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL).
|
Int J Cancer
|
2000
|
0.97
|
|
13
|
Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters.
|
Pediatr Blood Cancer
|
2006
|
0.95
|
|
14
|
The bisphosphonate pamidronate is a potent inhibitor of human osteosarcoma cell growth in vitro.
|
Anticancer Drugs
|
2001
|
0.92
|
|
15
|
Randomized clinical trials in children--ethical and methodological issues.
|
Curr Pharm Des
|
2010
|
0.91
|
|
16
|
Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
|
Ann Oncol
|
2004
|
0.88
|
|
17
|
Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia.
|
Leukemia
|
1998
|
0.87
|
|
18
|
Pegylated asparaginase in combination with high-dose methotrexate for consolidation in adult acute lymphoblastic leukaemia in first remission: a pilot study.
|
Br J Haematol
|
2003
|
0.86
|
|
19
|
All-trans-retinoic acid increases cytosine arabinoside cytotoxicity in HL-60 human leukemia cells in spite of decreased cellular ara-CTP accumulation.
|
Ann Oncol
|
1999
|
0.84
|
|
20
|
Asparagine concentration in plasma after 2,500 IU/m(2) PEG-asparaginase i.v. in children with acute lymphoblastic leukemia.
|
Klin Padiatr
|
2005
|
0.84
|
|
21
|
Simultaneous determination of all-trans-, 13-cis- and 9-cis-retinoic acid, their 4-oxo metabolites and all-trans-retinol in human plasma by high-performance liquid chromatography.
|
J Chromatogr B Biomed Appl
|
1996
|
0.83
|
|
22
|
Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL.
|
Leukemia
|
2003
|
0.83
|
|
23
|
[Improved treatment results in children with AML: Results of study AML-BFM 93].
|
Klin Padiatr
|
2001
|
0.82
|
|
24
|
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
|
Klin Padiatr
|
2002
|
0.82
|
|
25
|
Serum asparaginase activities and asparagine concentrations in the cerebrospinal fluid after a single infusion of 2,500 IU/m(2) PEG asparaginase in children with ALL treated according to protocol COALL-06-97.
|
Pediatr Blood Cancer
|
2006
|
0.81
|
|
26
|
Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity.
|
Br J Haematol
|
2000
|
0.81
|
|
27
|
Determination of paclitaxel in biological fluids by micellar electrokinetic chromatography.
|
J Chromatogr A
|
1996
|
0.81
|
|
28
|
Augmentation of 1-beta-D-arabinofuranosylcytosine (Ara-C) cytotoxicity in leukaemia cells by co-administration with antisignalling drugs.
|
Eur J Cancer
|
1998
|
0.81
|
|
29
|
Chemically induced isomerization and differential uptake modulate retinoic acid disposition in HL-60 cells.
|
FASEB J
|
1998
|
0.80
|
|
30
|
[Pharmacokinetic aspects of oral administration of etoposide].
|
Klin Padiatr
|
1998
|
0.80
|
|
31
|
Trofosfamide: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the oral treatment of cancer.
|
Anticancer Drugs
|
1997
|
0.80
|
|
32
|
Quantification of daunorubicin and daunorubicinol in plasma by capillary electrophoresis.
|
J Chromatogr B Biomed Sci Appl
|
2001
|
0.80
|
|
33
|
Pharmacokinetic monitoring of intravenous cyclosporine A in pediatric stem-cell transplant recipients. The trough level is not enough.
|
Pediatr Transplant
|
2008
|
0.80
|
|
34
|
Development of hypertension in neuroblastoma during therapy: a case report.
|
Med Pediatr Oncol
|
1993
|
0.80
|
|
35
|
Drug monitoring of low-dose PEG-asparaginase (Oncaspar) in children with relapsed acute lymphoblastic leukaemia.
|
Br J Haematol
|
2001
|
0.79
|
|
36
|
Inhibition of hypercoagulation by antithrombin substitution in E. coli L-asparaginase-treated children.
|
Eur J Haematol
|
1996
|
0.79
|
|
37
|
[HIT-GBM: multicenter study of treatment of children with malignant glioma].
|
Klin Padiatr
|
1996
|
0.79
|
|
38
|
Investigation of the major human hepatic cytochrome P450 involved in 4-hydroxylation and N-dechloroethylation of trofosfamide.
|
Cancer Chemother Pharmacol
|
1999
|
0.79
|
|
39
|
[Non-commercial clinical trials--who will be the legal sponsor? Sponsorship of investigator-initiated clinical trials according to the German Drug Law].
|
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz
|
2006
|
0.78
|
|
40
|
Asparaginase decreases clotting factors in vitro: a possible pitfall?
|
Int J Clin Lab Res
|
1995
|
0.78
|
|
41
|
Short-term versus continuous infusion: no influence on ifosfamide side-chain metabolism.
|
Eur J Cancer
|
1995
|
0.78
|
|
42
|
Population pharmacokinetic approach to compare oral and i.v. administration of etoposide.
|
Anticancer Drugs
|
1999
|
0.77
|
|
43
|
Excretion kinetics of ifosfamide side-chain metabolites in children on continuous and short-term infusion.
|
Int J Clin Pharmacol Ther
|
1998
|
0.77
|
|
44
|
Effects and interaction of 7-hydroxy methotrexate and methotrexate in leukaemic cells ex vivo measured by the thymidylate synthase inhibition assay.
|
Cancer Chemother Pharmacol
|
2005
|
0.77
|
|
45
|
Second temporal remission in a malignant glioma with trofosfamide and etoposide: a case report.
|
Klin Padiatr
|
1996
|
0.77
|
|
46
|
Phase II study of gemcitabine in children with relapsed leukemia.
|
Pediatr Blood Cancer
|
2006
|
0.77
|
|
47
|
Therapeutic drug monitoring of doxorubicin in paediatric oncology using capillary electrophoresis.
|
Electrophoresis
|
1998
|
0.77
|
|
48
|
Drug monitoring of PEG-asparaginase treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma.
|
Leuk Lymphoma
|
2002
|
0.76
|
|
49
|
Ethical approval for multicentre clinical trials in children. Contrasting systems in three European countries.
|
Eur J Cancer
|
2002
|
0.76
|
|
50
|
Modified total lymphoid irradiation and low dose corticosteroids in progressive multiple sclerosis.
|
J Neurol Sci
|
1997
|
0.76
|
|
51
|
[The control of hip dysplasia in Switzerland. A retrospect of the past 24 years].
|
Schweiz Arch Tierheilkd
|
1995
|
0.76
|
|
52
|
Resistance to activated protein C (APCR) in children with acute lymphoblastic leukaemia--the need for a prospective multicentre study.
|
Blood Coagul Fibrinolysis
|
1995
|
0.76
|
|
53
|
Loss of activity of Erwinia asparaginase on repeat applications.
|
J Clin Oncol
|
1995
|
0.75
|
|
54
|
Simulation tool for schedule-dependent etoposide exposure based on pharmacokinetic findings published in the literature.
|
Anticancer Drugs
|
2001
|
0.75
|
|
55
|
Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.
|
Br J Cancer Suppl
|
1992
|
0.75
|
|
56
|
Unphysiological effects contributing to asparaginase toxicity in vitro.
|
Am J Physiol
|
1998
|
0.75
|
|
57
|
Therapy of childhood acute myelogenous leukemias.
|
Ann Hematol
|
1996
|
0.75
|
|
58
|
Determination of (E)-5-(2-bromovinyl)-2'-deoxyuridine in plasma and urine by capillary electrophoresis.
|
J Chromatogr B Biomed Sci Appl
|
1999
|
0.75
|
|
59
|
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells.
|
Leukemia
|
2001
|
0.75
|
|
60
|
Meeting report: pharmacology in pediatric oncology. Summary of the 10th international expert meeting of the Kind Philipp Foundation for leukemia research, June 10 - 13, 2001 at the Schloss Reisensburg, Günzburg an der donau.
|
Klin Padiatr
|
2002
|
0.75
|
|
61
|
Changes in coagulation and fibrinolysis in childhood ALL: a two-step dose reduction of one E. coli asparaginase preparation.
|
Br J Haematol
|
1996
|
0.75
|
|
62
|
Determination of idarubicin and idarubicinol in plasma by capillary electrophoresis.
|
J Chromatogr B Biomed Sci Appl
|
1997
|
0.75
|
|
63
|
Influence of two different Escherichia coli asparaginase preparations on fibrinolytic proteins in childhood ALL.
|
Haematologica
|
1996
|
0.75
|
|
64
|
Monitoring paracetamol metabolism after single and repeated administration in pediatric patients with neoplastic diseases.
|
Int J Clin Pharmacol Ther
|
2007
|
0.75
|
|
65
|
MOON-test - determination of motor performance in the pediatric oncology.
|
Klin Padiatr
|
2013
|
0.75
|
|
66
|
[Prognosis of children with acute myelocytic leukemia after first relapse].
|
Klin Padiatr
|
1998
|
0.75
|
|
67
|
Capillary electrophoretic drug monitoring of methotrexate and leucovorin and their metabolites.
|
J Chromatogr B Biomed Sci Appl
|
1998
|
0.75
|
|
68
|
Use of PEG-asparaginase in the treatment of patients with solid tumors.
|
Cancer Chemother Pharmacol
|
2001
|
0.75
|
|
69
|
Pharmacokinetics of trofosfamide and its dechloroethylated metabolites.
|
Cancer Chemother Pharmacol
|
1997
|
0.75
|
|
70
|
Pharmacokinetics of anticancer drugs in vitro.
|
Adv Exp Med Biol
|
1999
|
0.75
|
|
71
|
[Solid state sample preparation of ifosfamide and dechloroethyl- metabolites in biological material. 2. Consideration of the separation mechanism].
|
Pharmazie
|
1993
|
0.75
|
|
72
|
[Effect of etamsylate on hemorrhagic diathesis of children with oncologic diseases. Retrospective matched-pair analysis of 64 patients in a study of 100 patients of the Münster University Pediatric Clinic].
|
Klin Padiatr
|
1991
|
0.75
|
|
73
|
[Drug development in paediatric oncology].
|
Klin Padiatr
|
2006
|
0.75
|
|
74
|
Changes in coagulation and fibrinolysis in childhood acute lymphoblastic leukaemia re-induction therapy using three different asparaginase preparations.
|
Eur J Pediatr
|
1997
|
0.75
|
|
75
|
[Antiinfectious prophylaxis in pediatric oncology. Work group "Quality Assurance" of Society for Pediatric Oncology and Hematology (GPOH)].
|
Klin Padiatr
|
1999
|
0.75
|
|
76
|
[Solid phase-sample preparation of ifosfamide and chloroethyl metabolites in biological material. 1. Determination in plasma and urine].
|
Pharmazie
|
1992
|
0.75
|
|
77
|
[Intracellular retention of cytarabine-triphosphate (Ara-CTP) in blasts of children with acute lymphoblastic leukemia. Correlation with clinical course parameters].
|
Klin Padiatr
|
1996
|
0.75
|